Advances in antiretroviral therapy.
The 16th Conference on Retroviruses and Opportunistic Infections maintained its tradition of being recognized as the preeminent forum for detailing the state-of-the-art of antiretroviral therapy. Abundant new and updated information was presented on investigational drugs, approaches to the management of treatment-naive and -experienced patients, the use of drugs for prevention of mother-to-child HIV-1 transmission, and antiretroviral drug resistance. Of particular note were the continued advances in antiretroviral treatment and research emanating from resource-limited settings and the presentation of the results of 2 much-anticipated, phase III trials of interleukin-2, ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomized International Trial) and SILCAAT (Subcutaneous, Recombinant Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Receiving Active Antiretroviral Therapy).
Wilkin
Timothy J
TJ
Weill Medical College of Cornell University, New York, NY, USA.
Taylor
Barbara
B
Olender
Susan
S
Hammer
Scott M
SM
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods / Q000639:trends*; D002986:Clinical Trials as Topic; D003906:Developing Countries; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D015507:Drugs, Investigational; D006801:Humans; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D015507:Drugs, Investigational